VEGFA and age-related macular degeneration: In contrast to this extraordinary potential, to date there is only one aptamer-based drug approved by the US Food and Drug Administration: Macugen (pegaptanib sodium), selected against the vascular endothelial growth factor (VEGF) and used for the treatment of neovascular age-related macular degeneration (AMD) in humans [41].